Compare TG Therapeutics Inc (TGTX) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.73. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| TGTX | VTIP | |
|---|---|---|
Market Cap | $8.53B | — |
Sector | Health | — |
52-Week High | $59.06 | $50.75 |
52-Week Low | $26.94 | $49.39 |
Enterprise Value | $8.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
VTIP trades at $49.75 with minimal daily movement (+0.04%). Technical indicators show a bearish bias with moving averages signaling caution, while oscillators remain neutral. The ETF focuses on short-term inflation-protected securities, offering minimal interest-rate sensitivity. Recent institutional activity includes 55 North Private Wealth increasing its position by 12.2% in Q2 2026.
Outlook remains cautious given bearish technical signals and persistent inflation concerns. The fund provides inflation hedging with reduced rate risk, but limited growth potential and competitive TIPS alternatives present challenges. Investors seeking short-duration inflation protection may find value, though overall market sentiment suggests tempered expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
